Pure Global
NCT06368440

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

A Single-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Doses in Japanese and Chinese Healthy Participants
AstraZeneca·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
AZD6793
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
AstraZeneca
Location
Glendale, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 15, 2024
End date
Oct 04, 2024
Enrollment
40 participants
Primary outcome

Part 1 (SAD): Number of Participants with Adverse Events,Part 2 (MAD): Number of Participants with Adverse Events

Summary

The main purpose of this study is to assess the safety, tolerability and pharmacokinetics
 (PK) of oral AZD6793 in healthy Japanese and Chinese participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06368440
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06368440 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.